Key result
Novel Mfn2-based nomogram links high-risk status to ~9-fold higher 5-year cardiogenic death in ICM.
Why the study?
The association between Mitofusin2 (Mfn2) genotype and plasma levels and the long-term prognosis of ischemic cardiomyopathy (ICM) needed investigation to establish a predictive nomogram for risk assessment.
Does a prognostic nomogram incorporating Mfn2 genetic polymorphisms, plasma Mfn2 levels, and clinical variables accurately predict long-term cardiogenic death in patients with ischemic cardiomyopathy?
Cohort (n=1,092)
No
Does a prognostic nomogram incorporating Mfn2 genetic polymorphisms, plasma Mfn2 levels, and clinical variables accurately predict long-term cardiogenic death in patients with ischemic cardiomyopathy?
A novel clinical-genetic nomogram integrating plasma Mfn2 levels, Mfn2 gene polymorphisms (rs1042842, rs2295281, rs2236054), and routine clinical variables accurately stratifies 1-, 3-, and 5-year cardiogenic mortality risk in patients with ischemic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Mfn2 nomogram may refine ICM risk stratification; hypothesis-generating and requires prospective validation before clinical use.
Objective To investigate the association between Mitofusin2 (Mfn2) genotype and its plasma levels with long-term prognosis of ischemic cardiomyopathy (ICM), and to establish and validate a predictive nomogram for long-term prognosis of ICM, thereby providing a theoretical basis for risk assessment of ICM. Methods This study included 1092 ICM patients who underwent follow-up at 3, 6, 12, 24, 36, 48, and 60 months after first diagnosed with ICM. Based on follow-up outcomes, patients were categorized into survival and death groups. All patients were randomly divided into a training set (n = 764) and a validation set (n = 328). Univariate Cox regression analysis was performed on the training set. Variables with P < 0.1 in univariate analysis underwent Lasso regression analysis. Multivariate Cox regression models were constructed using selected variables by lasso regression analysis.followed performed model validation. Performance was evaluated using ROC curves, calibration curves, and decision curve analysis (DCA). Results Multivariate Cox regression analysis revealed that plasma Mfn2 levels, heart rate, serum sodium, treatment with PCI or CABG, beta-blocker use, LVDD, and mutations at SNP loci rs1042842, rs2295281, and rs2236054 were independent predictors of long-term ICM prognosis ( P < 0.05). The nomogram constructed based on these findings demonstrated excellent discriminatory ability in both the training and validation cohorts (AUCs: 0.824 [1 year], 0.809 [3 years], and 0.877 [5 years] in the training set; and 0.808 (1 year), 0.767 (3 years), and 0.790 (5 years) in the validation set). The model demonstrated good consistency between observed and predicted values, indicating strong clinical usefulness. Conclusion Elevated plasma Mfn2 levels and genetic mutations at rs223605 may represent protective factors influencing long-term prognosis in ICM, whereas mutations at rs1042842 and rs2295281 may constitute risk factors for poor long-term outcomes in ICM.
No takes yet. Share an insight, caveat, or question.
Naman et al. (2026) conducted a cohort in Ischemic cardiomyopathy (ICM) (n=1,092). Mfn2 genetic polymorphisms (rs1042842, rs2295281, rs2236054), plasma Mfn2 levels, and high-risk nomogram score (>260.7161) vs. Low-risk nomogram score (<=260.7161) or wild-type Mfn2 genotype was evaluated on 5-year cardiogenic death (high-risk vs low-risk nomogram score group) (HR 9.003, 95% CI 6.720-12.062, p=<0.001). A prognostic nomogram incorporating plasma Mfn2 levels and Mfn2 SNPs stratified 5-year cardiogenic death risk in ICM patients.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: